Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients

Clin Exp Med. 2018 Feb;18(1):101-107. doi: 10.1007/s10238-017-0469-y. Epub 2017 Aug 18.

Abstract

The aim of the study was to look for any association of MTR 2756A>G and MTRR 66A>G gene polymorphisms with clinical phenotype, methotrexate (MTX) treatment response, and MTX-induced adverse events in South Indian Tamil patients with rheumatoid arthritis (RA). A total of 335 patients with RA were investigated. MTR 2756A>G gene polymorphism was analyzed by PCR-RFLP, and MTRR 66A>G SNP was analyzed by TaqMan 5' nuclease assay. The allele frequencies were compared with HapMap groups. MTR 2756G allele was found to be associated with risk of developing RA. The allele frequencies of MTR 2756A>G and MTRR 66A>G SNPs in controls differed significantly when compared with HapMap groups. Neither of the SNPs influenced the MTX treatment outcome and adverse effects. Neither of the SNPs seems to be associated with MTX treatment outcome and adverse events in South Indian Tamil patients with RA.

Keywords: Adverse events; MTR; MTRR; Methotrexate; Rheumatoid arthritis; South Indian Tamils; Treatment response.

MeSH terms

  • 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / genetics*
  • Adult
  • Antirheumatic Agents / administration & dosage*
  • Arthritis, Rheumatoid / drug therapy*
  • Female
  • Ferredoxin-NADP Reductase / genetics*
  • Gene Frequency
  • Genetic Association Studies
  • Humans
  • India
  • Male
  • Methotrexate / administration & dosage*
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Polymorphism, Single Nucleotide*
  • Prospective Studies
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • methionine synthase reductase
  • Ferredoxin-NADP Reductase
  • 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
  • MTR protein, human
  • Methotrexate